Evoke Pharma (NASDAQ:EVOK) Earns Sell Rating from Analysts at StockNews.com

Stock analysts at StockNews.com began coverage on shares of Evoke Pharma (NASDAQ:EVOK) in a research report issued to clients and investors on Tuesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Evoke Pharma Price Performance

NASDAQ:EVOK opened at $3.62 on Tuesday. The firm has a 50 day simple moving average of $4.68 and a 200-day simple moving average of $4.78. The firm has a market cap of $5.38 million, a PE ratio of -0.33 and a beta of 0.16. Evoke Pharma has a 1-year low of $3.44 and a 1-year high of $12.32.

Hedge Funds Weigh In On Evoke Pharma

A hedge fund recently bought a new position in Evoke Pharma stock. Corsair Capital Management L.P. purchased a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma as of its most recent filing with the Securities and Exchange Commission (SEC).

About Evoke Pharma

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.